Opioid-class REMS unlikely to halt abuse; U.S. trade office IDs Brazil, China, India among counterfeit hot spots;

> Opioid REMS implementation costs will be passed along to consumers and third-party payers, despite their "unlikely" ability to reduce or mitigate opioid abuse. Article

> The Office of the United States Trade Representative cites Brazil, China, India, Indonesia and Russia as areas of concern for the proliferation of counterfeit drugs. Article

> Catalent has named Barry Russell president of its commercial packaging group. Release

> Big-three drug distributor McKesson's yearly outlook beat Wall Street's estimate. Item

> Increasing challenges balanced by sound fundamentals and healthy growth prospects will yield stable credit risk profiles for Indian pharma companies in the international markets, says CRISIL Ratings. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.